Ph.D. in organic chemistry from Université of Lyon 1 (2015) and Post-doc at EPFL Lausanne and University of Toronto. 

Research focus: Medicinal chemistry from hit identification to lead optimization. Expertise in the design and synthesis of small molecules in integrating SAR and ADME properties to drive medicinal chemistry strategy. 

Sebastien also worked as a medicinal chemist at Nuchem Science, Evotec SA and adMare Bioinnovation, before joining MFI. 

Ph.D. From Sorbonne Université and Ecole Polytechnique. Research focus: DFT and Organic synthesis. Agathe also worked at the Broad Institute in Cambridge MA and completed an internship at McGill under the supervision of Pr. Nicolas Moitessier.

Ph. D. from the University of Tokyo. Research focus: structure and ligand-based drug design. Matej previously worked at the National Institute of Chemistry in Slovenia.

Ph.D. Chemistry and B.Sc. Pharmacology from McGill University. Anne has worked in the Department of Pharmacology & Therapeutics at McGill University. Research focus: Structure-based drug design and organic synthesis.

BSC student in Computer Science and Bioinformatics at University of Waterloo. Wasay has previously worked as a full-stack developer at PointClickCare, a backend developer at Toyota, and a Software Developer in Test at Plooto.

B.Eng. in Software Engineering from McGill university. Mathieu has previous experience in technical consulting at Deloitte, as well as in full-stack software development at CAE.

Ph.D. in Chemistry from McGill University, M.Sc. and B.Sc. in Chemistry from the University of Manitoba. Research focus: structure-based drug design, development of biochemical and biophysical assays to characterize drug-target interactions.

B.Eng. student in Bioengineering at McGill University with a minor in Applied AI. Eva specializes in computational methods in bioengineering and biomedical engineering. She has worked at Bowhead Health and as a research assistant between the Departments of Chemistry and Bioengineering. She is currently contributing to a microfluidic detection device that passively traps airborne particles and measures them electrochemically.

M.Sc. in Pharmacy from the School of Pharmacy, University of Waterloo, where his research — funded by MITACS — focused on developing a knowledge-driven drug discovery platform for facilitating inhibitor development against Betacoronavirus main proteases.

MSc research areas: drug discovery, with an emphasis on machine learning, software development, and data analysis. These culminated in two peer-reviewed publications and two conference oral presentations.
Shubham also holds an Honours Degree in Biochemistry (CSC Accredited) and a Joint Honours Degree in Mathematics from the University of Waterloo

Dr. R.J. Swett is a Computational Chemist with over a decade of pharma experience. She holds a PhD from Wayne State University and completed a Presidential Postdoc at Novartis partnered with Stanford. Dr. Swett has worked on rare disease and oncology targets at Vertex Pharmaceuticals and Relay Therapeutics. She is currently the Director of Computational Chemistry Innovation at X-Chem.

Didier is a seasoned investor and leader in the Canadian life sciences sector, with experience at Investissement Quebec and Fonds de solidarité FTQ. He has managed seed investment funds, collaborated with entrepreneurs, and advises life sciences clients. Didier holds an MBA in Technology Management and an engineering degree in Material Sciences.